天然产物研究与开发2026，Vol.38Issue(8)：1713-1721,9.DOI:10.16333/j.1001-6880.2026.8.010
白花树枝叶化学成分及其抗动脉粥样硬化网络药理学研究
Chemical constituents from the branches and leaves of Styrax tonkinensis and network pharmacology study on their anti-atherosclerotic effects
摘要
Abstract
This study investigated the chemical constituents of Styrax tonkinensis(Pierre)Craib ex Hart.branches and leaves and their anti-atherosclerotic mechanism.The ethyl acetate extract of S.tonkinensis was isolated and purified using MCI,silica gel,ODS,Sephadex LH-20 column chromatography,and semi-preparative HPLC.Compound structures were identified through physicochemical properties,NMR spectroscopy,and literature comparison.Network pharmacology and molecular docking were employed to explore anti-atherosclerotic mechanisms.Nine compounds were isolated:5α,6α-epoxy-3β-hydroxymegastigm-7-en-9-one(1),3-hydroxy-β-ionone(2),E epipinoresinol(3),9-methoxypinoresinol(4),puviatilol(5),(-)-eudesmin(6),methyl 3-(3,5-di-tert-butyl-4-hydroxyphenyl)propanoate(7),4-[[(3R,4R)-4-[(3,4-dimethoxybenzyl)methyl]tetra-hydro-3-furanyl]methyl]-2-methoxy phenol(8),kaempferol(9).Among them,compounds 1,2,and 4-9 were isolated from the genus Styrax for the first time.Network pharmacology results revealed that the nine compounds primarily target multiple proteins including prostaglandin-endoperoxide synthase 2(PTGS2),albumin(ALB),and phosphatidylinositol-4,5-bisphos-phate 3-kinase catalytic subunit alpha(PIK3CA).KEGG pathway enrichment analysis identified key signaling pathways such as the phosphatidylinositol 3-kinase(PI3K)/protein kinase B(AKT)and Janus kinase(JAK)/signal transducer and activa-tor of transcription(STAT)pathways.This work provides the first systematic chemical analysis of S.tonkinensis branches and leaves,offering a foundation for further research.关键词
白花树枝叶/化学成分/动脉粥样硬化/网络药理学/分子对接Key words
branches and leaves of Styrax tonkinensis/chemical constituents/atherosclerosis/network pharmacology/molecular docking分类
医药卫生引用本文复制引用
郭众天,时若兰,谢琳,罗琼,谭婉菁,朱立彬,王峰..白花树枝叶化学成分及其抗动脉粥样硬化网络药理学研究[J].天然产物研究与开发,2026,38(8):1713-1721,9.基金项目
广东省普通高校生物医药与健康重点领域专项(2022ZDZX2035) （2022ZDZX2035）
